TPP medicines proposals would cost $205 million in one year

A study by health experts Deborah Gleeson, Ruth Lopert and Hazel Moir  published in late December 2014 examines the potential costs  for Australia of a proposal  in the leaked  intellectual property chapter of the Trans-Pacific Trade deal. which would extend test data protection for biologic medicines and  delay the availability of cheaper generic versions.  The study uses Medicare Australia expenditure data for the ten most expensive biologic drugs on the Pharmaceutical Benefits Scheme (PBS)to estimate the potential costs to Australian taxpayers of the proposed extension.  Such an extension would have cost over $205 million  in the year 2013-14 alone .